Ignite Creation Date:
2024-05-05 @ 11:46 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00122460
Status:
COMPLETED
Last Update Posted:
2014-07-23
First Post:
2005-07-19
Brief Title:
Cetuximab Erbitux in Combination With Cisplatin or Carboplatin and 5-Fluorouracil in the First Line Treatment of Subjects With Recurrent andor Metastatic Squamous Cell Carcinoma of the Head and Neck EXTREME
Sponsor:
Merck KGaA Darmstadt Germany
Organization:
Merck KGaA Darmstadt Germany
Organization Data
Organization:
Merck KGaA Darmstadt Germany
Class:
INDUSTRY
Study ID:
EMR 62202-002
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Merck KGaA Darmstadt Germany
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None